Intranasal self-amplifying RNA SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission

Jennewein, Madeleine F.; Beaver, Samuel; Battisti, Peter; Bakken, Julie; Hanson, Derek; Mohamath, Raodoh; Singh, Jasneet; Cross, Noah; Reed, Sierra; Gerhardt, Alana; Casper, Corey; Voigt, Emily A.

doi:10.1101/2022.11.10.515993

Cited by 1 publication

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 75 Additionally, the entire complex can be readily lyophilized and stored at room temperature for 8 months or refrigerated for nearly two years. 76 This thermostability is an improvement on what is seen with previous LNP formulations and could significantly improve distribution of vaccines. The AAHI‐SC2 vaccine was demonstrated to produce a high serum‐specific IgG and SARS‐CoV‐2 Wuhan‐strain specific neutralizing antibodies.…”

Section: Current Clinical Trialsmentioning

confidence: 92%

Vaccine adjuvants for infectious disease in the clinic

Goetz,

Thotathil,

Zhao

et al. 2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Adjuvants, materials added to vaccines to enhance the resulting immune response, are important components of vaccination that are many times overlooked. While vaccines always include an antigen to tell the body what to vaccinate to, of equal importance the adjuvant provides the how, a significant factor in producing a complete response. The adjuvant space has been slow to develop with the first use of an adjuvant in a licensed vaccine occurring in the 1930s, and remaining the only adjuvant in licensed vaccines for the next 80 years. However, with vaccination at the forefront of protection against new and complex pathogens, it is important to consider all components when designing an effective vaccine. Here we summarize the adjuvant space in licensed vaccines as well as the novel adjuvant space in clinical trials with a specific focus on the materials utilized and their resulting impact on the immune response. We discuss five major categories of adjuvant materials: aluminum salts, nanoparticles, viral vectors, TLR agonists, and emulsions. For each category, we delve into the current clinical trials space, the impact of these materials on vaccination, as well as some of the ways in which they could be improved. Adjuvants present an exciting opportunity to improve vaccine responses and stability, this review will help inform about the current progress of this space.Translational impact statementIn the aftermath of the COVID‐19 pandemic, vaccines for infectious diseases have come into the spotlight. While antigens have always been an important focus of vaccine design, the adjuvant is a significant tool for enhancing the immune response to the vaccine that has been largely underdeveloped. This article provides a broad review of the history of adjuvants and, the current vaccine adjuvant space, and the progress seen in adjuvants in clinical trials. There is specific emphasis on the material landscape for adjuvants and their resulting mechanism of action. Looking ahead, while the novel vaccine adjuvant space features exciting new technologies and materials, there is still a need for more to meet the protective needs of new and complex pathogens.

show abstract

Section: Current Clinical Trialsmentioning

confidence: 92%